Presentation: Anaemia and CKD: New treatment options for an old problem
Erythropoietic stimulating agents have been the cornerstone for managing anaemia of chronic kidney disease for over 30 years. Hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) now provide a new treatment option. This presentation will update the management of anaemia of CKD and the evidence behind HIF-PHIs and other agents.
Update Course Keynote Presentation PDF Slides

